Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash (CRL:NYSE)
· seekingalpha.com
Charles River to acquire Frontage bioanalysis and DMPK operations for $470M, expanding clinical testing capabilities.
The market is projected to grow from about $6 billion in 2026 to $8 billion–$9 billion by 2031, with annual growth of 6%–8%; biologics and complex modalitie...